Cockburn A G, Vugrin D, Batata M, Hajdu S, Whitmore W F
Cancer. 1984 May 1;53(9):1991-4. doi: 10.1002/1097-0142(19840501)53:9<1991::aid-cncr2820530931>3.0.co;2-6.
Anaplastic seminoma constitutes approximately 17% of total experience with seminoma at Memorial Sloan-Kettering Cancer Center. Among 25 previously untreated patients, 11 (44%) were clinical Stage I, and 14 (56%) were clinical Stage II or III. Treatment of these 25 patients with the same regimens employed for classical seminoma yielded an overall 80% 5-year apparent cure rate. Survival rates were poor in eight previously treated patients referred with recurrence.